Recent Finacing
Recent Raise
OrsoBio is a clinical-stage biopharmaceutical developing mitochondrial protonophores and metabolic therapies for obesity, diabetes, and dyslipidemia; lead oral liver-targeted TLC-6740 is in Phase 1b, with ACC2 and LXR programs.
